Literature DB >> 9788425

Dosimetric properties of a novel brachytherapy balloon applicator for the treatment of malignant brain-tumor resection-cavity margins.

J F Dempsey1, J A Williams, J B Stubbs, T J Patrick, J F Williamson.   

Abstract

PURPOSE: This paper characterizes the dosimetric properties of a novel balloon brachytherapy applicator for the treatment of the tissue surrounding the resection cavity of a malignant brain tumor. METHODS AND MATERIALS: The applicator consists of an inflatable silicone balloon reservoir attached to a positionable catheter that is intraoperatively implanted into the resection cavity and postoperatively filled with a liquid radionuclide solution. A simple dosimetric model, valid in homogeneous media and based on results from Monte Carlo photon-transport simulations, was used to determine the dosimetric characteristics of spherical geometry balloons filled with photon-emitting radionuclide solutions. Fractional depth-dose (FDD) profiles, along with activity densities, and total activities needed to achieve specified dose rates were studied as a function of photon energy and source-containment geometry. Dose-volume histograms (DVHs) were calculated to compare idealized balloon-applicator treatments to conventional 125I seed volume implants.
RESULTS: For achievable activity densities and total activities, classical low dose rate (LDR) treatments of residual disease at distances of up to 1 cm from the resection cavity wall are possible with balloon applicators having radii between 0.5 cm and 2.5 cm. The dose penetration of these applicators increases approximately linearly with balloon radius. The FDD profile can be made significantly more or less penetrating by combining selection of radionuclide with source-geometry manipulation. Comparisons with 125I seed-implant DVHs show that the applicator can provide a more conformal therapy with no target tissue underdosing, less target tissue overdosing, and no healthy tissue "hot spots;" however, more healthy tissue volume receives a dose of the prescribed dosage or less.
CONCLUSIONS: This device, when filled with 125I solution, is suitable for classical LDR treatments and may be preferable to 125I interstitial-seed implants in several respects. Manipulation of the dosimetric properties of the device can improve its characteristics for brain tumor treatment and may make it suitable for boosting the lumpectomy margins in conservative breast cancer treatment.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9788425     DOI: 10.1016/s0360-3016(98)00215-6

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  9 in total

1.  Injectable Hydrogels for Localized Chemotherapy and Radiotherapy in Brain Tumors.

Authors:  Pilar de la Puente; Nicole Fettig; Micah J Luderer; Abbey Jin; Shruti Shah; Barbara Muz; Vaishali Kapoor; Sreekrishna M Goddu; Noha Nabil Salama; Christina Tsien; Dinesh Thotala; Kooresh Shoghi; Buck Rogers; Abdel Kareem Azab
Journal:  J Pharm Sci       Date:  2017-11-21       Impact factor: 3.534

Review 2.  Brachytherapy for brain tumors.

Authors:  Todd W Vitaz; Peter C Warnke; Viviane Tabar; Philip H Gutin
Journal:  J Neurooncol       Date:  2005-05       Impact factor: 4.130

Review 3.  Stereotactic radiosurgery and interstitial brachytherapy for glial neoplasms.

Authors:  M W McDermott; M S Berger; Sandeep Kunwar; Andrew T Parsa; P K Sneed; David A Larson
Journal:  J Neurooncol       Date:  2004 Aug-Sep       Impact factor: 4.130

Review 4.  Smart Radiation Therapy Biomaterials.

Authors:  Wilfred Ngwa; Francis Boateng; Rajiv Kumar; Darrell J Irvine; Silvia Formenti; Twalib Ngoma; Carsten Herskind; Marlon R Veldwijk; Georg Lars Hildenbrand; Michael Hausmann; Frederik Wenz; Juergen Hesser
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-11-01       Impact factor: 7.038

Review 5.  Neurosurgical advances in the treatment of brain tumors.

Authors:  J J Olson
Journal:  Curr Oncol Rep       Date:  2000-09       Impact factor: 5.075

6.  Outcome of Adult Brain Tumor Consortium (ABTC) prospective dose-finding trials of I-125 balloon brachytherapy in high-grade gliomas: challenges in clinical trial design and technology development when MRI treatment effect and recurrence appear similar.

Authors:  L R Kleinberg; V Stieber; T Mikkelsen; K Judy; J Weingart; G Barnett; J Olson; S Desideri; X Ye; S Grossman
Journal:  J Radiat Oncol       Date:  2015-08-05

7.  Immediate post-operative brachytherapy prior to irradiation and temozolomide for newly diagnosed glioblastoma.

Authors:  J Dawn Waters; Brent Rose; David D Gonda; Daniel J Scanderbeg; Michelle Russell; John F Alksne; Kevin Murphy; Bob S Carter; Joshua Lawson; Clark C Chen
Journal:  J Neurooncol       Date:  2013-05-15       Impact factor: 4.130

8.  Feasibility of removable balloon implant for simultaneous magnetic nanoparticle heating and HDR brachytherapy of brain tumor resection cavities.

Authors:  Paul R Stauffer; Dario B Rodrigues; Robert Goldstein; Thinh Nguyen; Yan Yu; Shuying Wan; Richard Woodward; Michael Gibbs; Ilya L Vasilchenko; Alexey M Osintsev; Voichita Bar-Ad; Dennis B Leeper; Wenyin Shi; Kevin D Judy; Mark D Hurwitz
Journal:  Int J Hyperthermia       Date:  2020       Impact factor: 3.914

9.  Feasibility of intratumoral 165Holmium siloxane delivery to induced U87 glioblastoma in a large animal model, the Yucatan minipig.

Authors:  Mehrdad Khoshnevis; Claude Carozzo; Richard Brown; Manuel Bardiès; Catherine Bonnefont-Rebeix; Sara Belluco; Christophe Nennig; Lionel Marcon; Olivier Tillement; Hélène Gehan; Cédric Louis; Ilyes Zahi; Thierry Buronfosse; Thierry Roger; Frédérique Ponce
Journal:  PLoS One       Date:  2020-06-18       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.